PAVmed Is Maintained at Buy by Ascendiant Capital
Express News | Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $21
PAVmed Analyst Ratings
Earnings Call: PAVmed Reports Growth and Strategic Moves in Q2 2024
Earnings Call Summary | PAVmed(PAVM.US) Q2 2024 Earnings Conference
Q2 2024 PAVmed Inc Earnings Call
PAVmed Shares Informal Financial Performance Insights
PAVmed Q2 EPS $(1.19) Beats $(1.45) Estimate, Sales $979.00K Miss $1.20M Estimate
PAVmed 2Q Rev $979,000 >PAVM
PAVmed 2Q Loss $10.9M >PAVM
Express News | PAVmed Provides Business Update and Second Quarter 2024 Financial Results
10-Q: Q2 2024 Earnings Report
PAVmed Q2 2024 Earnings Preview
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024
Lucid Diagnostics Announces Positive Data From Its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Population
Express News | PAVmed's Veris Health Subsidiary Launches Pilot Program With Ohio State University Comprehensive Cancer Center; First Patients Enrolled In Veris Cancer Care Platform
Express News | PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program With the Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Express News | PAVmed Inc : Ascendiant Capital Markets Cuts Target Price to $22 From $26
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and PAVmed (PAVM)
No Data
No Data